Display options
Cite
Fabregat I, Malfettone A, Soukupova J. New Insights into the Crossroads between EMT and Stemness in the Context of Cancer. J Clin Med. 2016;5(3)doi: 10.3390/jcm5030037.
Fabregat, I., Malfettone, A., & Soukupova, J. (2016). New Insights into the Crossroads between EMT and Stemness in the Context of Cancer. Journal of clinical medicine, 5(3), . https://doi.org/10.3390/jcm5030037
Fabregat, Isabel, et al. "New Insights into the Crossroads between EMT and Stemness in the Context of Cancer." Journal of clinical medicine vol. 5,3 (2016). doi: https://doi.org/10.3390/jcm5030037
Fabregat I, Malfettone A, Soukupova J. New Insights into the Crossroads between EMT and Stemness in the Context of Cancer. J Clin Med. 2016 Mar 12;5(3). doi: 10.3390/jcm5030037. PMID: 26985909; PMCID: PMC4810108.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2016 Mar 12;5(3). doi: 10.3390/jcm5030037.

New Insights into the Crossroads between EMT and Stemness in the Context of Cancer.

Journal of clinical medicine

Isabel Fabregat, Andrea Malfettone, Jitka Soukupova

Affiliations

  1. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona 08007, Spain. [email protected].
  2. Department of Physiological Sciences II, University of Barcelona, Barcelona 08007, Spain. [email protected].
  3. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona 08007, Spain. [email protected].
  4. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona 08007, Spain. [email protected].

PMID: 26985909 PMCID: PMC4810108 DOI: 10.3390/jcm5030037

Abstract

The epithelial-mesenchymal transition (EMT) is an example of cellular plasticity, where an epithelial cell acquires a mesenchymal-like phenotype that increases its migratory and invasive properties. Stemness is the ability of stem cells to proliferate in an asymmetric way that allows them to maintain the reservoir of undifferentiated cells with stem cell identity, but also to produce new differentiated cells. Initial works revealed that activation of the EMT program in epithelial cells induces the acquisition of stem cell properties, which in the context of cancer may contribute to the appearance of tumor initiating cells (TIC). However, a number of groups have recently reported that mesenchymal-epithelial transition (MET) is required for efficient metastatic colonization and that EMT may be not necessarily associated with stemness. In this review, we summarize recent findings that extend our knowledge about the crossroads between EMT and stemness and their relevance under physiological or pathological conditions.

Keywords: CD133; CD44; EMT; MET; Prrx; Snail; Transforming Growth Factor-β (TGF-β); Twist; Zeb; stem

References

  1. Cancer Res. 2001 Jul 1;61(13):5275-83 - PubMed
  2. Mol Cancer Res. 2002 Nov;1(1):68-78 - PubMed
  3. Nature. 2015 Nov 26;527(7579):472-6 - PubMed
  4. Nat Rev Cancer. 2007 Jun;7(6):415-28 - PubMed
  5. Stem Cells. 2015 Apr;33(4):1063-74 - PubMed
  6. Int J Cancer. 2015 Feb 15;136(4):E161-72 - PubMed
  7. Mol Cell Biochem. 2010 Jul;340(1-2):265-73 - PubMed
  8. Sci Signal. 2014 Sep 23;7(344):re8 - PubMed
  9. Nat Cell Biol. 2014 Jun;16(6):488-94 - PubMed
  10. Nat Med. 2015 Sep;21(9):989-97 - PubMed
  11. Int J Cancer. 2014 Sep 15;135(6):1356-68 - PubMed
  12. Cancer Metastasis Rev. 2012 Dec;31(3-4):553-68 - PubMed
  13. FEBS Lett. 2015 Jun 22;589(14):1577-87 - PubMed
  14. J Cell Physiol. 2011 May;226(5):1214-23 - PubMed
  15. Curr Pharm Des. 2014;20(17):2934-47 - PubMed
  16. Oncotarget. 2015 Sep 22;6(28):25161-74 - PubMed
  17. Front Oncol. 2014 Dec 11;4:358 - PubMed
  18. PLoS One. 2013 Jun 17;8(6):e66558 - PubMed
  19. J Clin Invest. 2012 May;122(5):1849-68 - PubMed
  20. Crit Rev Oncog. 2014;19(5):349-61 - PubMed
  21. Cell. 2009 Nov 25;139(5):871-90 - PubMed
  22. Cell Death Dis. 2011 Jul 07;2:e179 - PubMed
  23. Cell. 2004 Jun 25;117(7):927-39 - PubMed
  24. Cancer Res. 2012 Jul 1;72(13):3414-23 - PubMed
  25. Cell. 2014 Jul 31;158(3):579-92 - PubMed
  26. Exp Cell Res. 1999 Nov 1;252(2):281-91 - PubMed
  27. Cancer Cell. 2012 Dec 11;22(6):699-701 - PubMed
  28. Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19204-9 - PubMed
  29. Nat Cell Biol. 2009 Dec;11(12 ):1487-95 - PubMed
  30. Nat Cell Biol. 2000 Feb;2(2):84-9 - PubMed
  31. Adv Cancer Res. 2014;123:255-75 - PubMed
  32. Cancer Res. 2008 Feb 1;68(3):937-45 - PubMed
  33. Oncotarget. 2015 Apr 10;6(10 ):8313-22 - PubMed
  34. Nature. 2015 Sep 10;525(7568):256-60 - PubMed
  35. Science. 2013 Nov 8;342(6159):1234850 - PubMed
  36. Cell Adh Migr. 2014;8(4):418-28 - PubMed
  37. Curr Cancer Drug Targets. 2013 Nov;13(9):957-62 - PubMed
  38. Nat Med. 2015 Sep;21(9):998-1009 - PubMed
  39. Cancer Res. 2007 Dec 15;67(24):11721-31 - PubMed
  40. Cancer Res. 2009 Mar 15;69(6):2400-7 - PubMed
  41. BMC Cancer. 2014 Dec 11;14:932 - PubMed
  42. Oncogene. 2002 May 9;21(20):3241-6 - PubMed
  43. Cell Rep. 2015 Jan 13;10 (2):131-9 - PubMed
  44. Nat Cell Biol. 2000 Feb;2(2):76-83 - PubMed
  45. Hepatology. 2013 Dec;58(6):2032-44 - PubMed
  46. Oncotarget. 2015 Jan 30;6(3):1740-9 - PubMed
  47. Hepatology. 2012 Dec;56(6):2255-67 - PubMed
  48. BMC Cancer. 2014 Sep 27;14 :722 - PubMed
  49. Cell Stem Cell. 2015 Jan 8;16(1):67-79 - PubMed
  50. Nat Cell Biol. 2015 Jun;17(6):816-26 - PubMed
  51. Nature. 2015 Nov 26;527(7579):525-30 - PubMed
  52. Cell. 2008 May 16;133(4):704-15 - PubMed
  53. J Biol Chem. 2008 Jun 20;283(25):17635-51 - PubMed
  54. Development. 2005 Jul;132(14 ):3151-61 - PubMed
  55. Oncogene. 2004 Jan 15;23 (2):474-82 - PubMed
  56. Oncotarget. 2015 May 10;6(13):10697-711 - PubMed
  57. Nat Cell Biol. 2010 Oct;12 (10 ):982-92 - PubMed
  58. Cancer Res. 2014 Mar 1;74(5):1554-65 - PubMed
  59. Oncol Rep. 2010 Mar;23(3):827-31 - PubMed
  60. Drug Resist Updat. 2010 Aug-Oct;13(4-5):109-18 - PubMed
  61. Cell. 2012 Jan 20;148(1-2):349-61 - PubMed
  62. Cell Stem Cell. 2010 Jul 2;7(1):51-63 - PubMed
  63. Cancer Cell. 2002 Oct;2(4):279-88 - PubMed
  64. Int J Cancer. 2015 Dec 1;137(11):2566-77 - PubMed
  65. Mol Cancer. 2006 Dec 02;5:67 - PubMed
  66. Cancer Cell. 2012 Dec 11;22(6):725-36 - PubMed
  67. BMC Cancer. 2011 Sep 19;11:396 - PubMed
  68. Nat Cell Biol. 2011 Mar;13(3):317-23 - PubMed
  69. PLoS One. 2008 Aug 06;3(8):e2888 - PubMed
  70. Stem Cells. 2009 Sep;27(9):2059-68 - PubMed
  71. EMBO Mol Med. 2015 Apr 14;7(6):831-47 - PubMed
  72. Trends Cell Biol. 2015 Nov;25(11):675-86 - PubMed
  73. Nat Cell Biol. 2013 Apr;15(4):338-44 - PubMed
  74. Expert Opin Ther Targets. 2015 Feb;19(2):285-97 - PubMed
  75. Cancer Cell. 2012 Dec 11;22(6):709-24 - PubMed
  76. PLoS One. 2014 Apr 04;9(4):e93917 - PubMed
  77. Cell. 2012 Mar 2;148(5):1015-28 - PubMed
  78. Cancer Res. 2014 Nov 1;74(21):6330-40 - PubMed
  79. Mod Pathol. 2010 Mar;23 (3):450-7 - PubMed
  80. J Hepatol. 2011 Aug;55(2):351-8 - PubMed
  81. Genes Dev. 2004 May 15;18(10 ):1131-43 - PubMed
  82. Oncogene. 2016 Jun 2;35(22):2824-33 - PubMed
  83. Cell Rep. 2013 Dec 12;5(5):1228-42 - PubMed
  84. Blood. 2015 Jul 23;126(4):508-19 - PubMed
  85. J Cell Sci. 2010 Oct 15;123(Pt 20):3467-77 - PubMed
  86. Nature. 2015 Nov 19;527(7578):329-35 - PubMed
  87. Semin Cancer Biol. 2012 Oct;22(5-6):361-8 - PubMed
  88. J Cell Physiol. 2008 Jun;215(3):846-55 - PubMed
  89. Nat Rev Cancer. 2002 Jun;2(6):442-54 - PubMed

Publication Types